NCT06626126View on ClinicalTrials.gov

Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention

NANot yet recruitingINTERVENTIONAL

Enrollment

1,448

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2029

Conditions

Coronary Arterial Disease (CAD)Percutaneous Coronary InterventionLDL-cholesterolLipid Metabolism Disorders

Interventions

OTHER

ApoB-guided-LLT

Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets

OTHER

LDL-C-guided-LLT

Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.

Trial Locations (1)

700000

University Medical Center Ho Chi Minh City, Ho Chi Minh City

All Listed Sponsors

collaborator

University of Medicine and Pharmacy at Ho Chi Minh City

OTHER

lead

University Medical Center Ho Chi Minh City (UMC)

OTHER

NCT06626126 - Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter